p53-dependent ceramide response to genotoxic stress.

Both p53 and ceramide have been implicated in the regulation of growth suppression. p53 has been proposed as the "guardian of the genome" and ceramide has been suggested as a "tumor suppressor lipid. " Both molecules appear to regulate cell cycle arrest, senescence, and apoptosis. In this study, we investigated the relationship between p53 and ceramide. We found that treatment of Molt-4 cells with low concentrations of actinomycin D or gamma-irradiation, which activate p53-dependent apoptosis, induces apoptosis only in cells expressing normal levels of p53. In these cells, p53 activation was followed by a dose- and time-dependent increase in endogenous ceramide levels which was not seen in cells lacking functional p53 and treated similarly. Similar results were seen in irradiated L929 cells whereby the p53-deficient clone was significantly more resistant to irradiation and exhibited no ceramide response. However, in p53-independent systems, such as growth suppression induced by TNF-alpha or serum deprivation, ceramide accumulated irrespective of the upregulation of p53, indicating that p53 regulates ceramide accumulation in only a subset of growth-suppressive pathways. Finally, ceramide did not increase p53 levels when used at growth-suppressive concentrations. Also, when cells lacking functional p53, either due to mutation or the expression of the E6 protein of human papilloma virus, were treated with exogenous ceramide, there was equal growth suppression, cell cycle arrest, and apoptosis as compared with cells expressing normal p53. These results indicate that p53 is unlikely to function "downstream" of ceramide. Instead, they suggest that, in situations where p53 performs a critical regulatory role, such as the response to genotoxic stress, it functions "upstream" of ceramide. These studies begin to define a relationship between these two pathways of growth inhibition.

[1]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[2]  A. Fornace,et al.  The p53-dependent γ-Ray Response of GADD45 , 1994 .

[3]  D. Lane,et al.  p53 and Rb: their cellular roles. , 1994, Current opinion in cell biology.

[4]  A. Marchetti,et al.  mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[5]  Kathleen R. Cho,et al.  p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Y. Hannun Functions of Ceramide in Coordinating Cellular Responses to Stress , 1996, Science.

[7]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[8]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[9]  B. Vogelstein,et al.  Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.

[10]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[11]  A. Bielawska,et al.  Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. , 1990, The Journal of biological chemistry.

[12]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[13]  James Brugarolas,et al.  Radiation-induced cell cycle arrest compromised by p21 deficiency , 1995, Nature.

[14]  M. Muller,et al.  Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Green,et al.  Inhibition of ceramide-induced apoptosis by Bcl-2. , 1995, Cell death and differentiation.

[16]  K O'Rourke,et al.  Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. , 1995, Cell.

[17]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[18]  Seamus J. Martin,et al.  Acid Sphingomyelinase–Deficient Human Lymphoblasts and Mice Are Defective in Radiation-Induced Apoptosis , 1996, Cell.

[19]  Junying Yuan,et al.  Human ICE/CED-3 Protease Nomenclature , 1996, Cell.

[20]  P. O'Connor,et al.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. , 1994, Science.

[21]  J. Little,et al.  Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. , 1995, Oncogene.

[22]  J. Jaffrezou,et al.  Daunorubicin‐induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. , 1996, The EMBO journal.

[23]  D. Lane,et al.  What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? , 1993 .

[24]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[25]  Y. Hannun,et al.  Programmed cell death induced by ceramide. , 1993, Science.

[26]  Y. Hannun,et al.  Phospholipase A2 Is Necessary for Tumor Necrosis Factor α-induced Ceramide Generation in L929 Cells* , 1997, The Journal of Biological Chemistry.

[27]  Yi-Song Wang,et al.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. , 1994, Cancer research.

[28]  L. Wiesmüller,et al.  p53 Protein Exhibits 3′-to-5′ Exonuclease Activity , 1996, Cell.

[29]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[30]  Y. Hannun,et al.  The sphingomyelin cycle and the second messenger function of ceramide. , 1994, The Journal of biological chemistry.

[31]  L. Daniel,et al.  1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. , 1994, The Journal of biological chemistry.

[32]  A. Bielawska,et al.  Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. , 1992, The Journal of biological chemistry.

[33]  M. Pushkareva,et al.  Ceramide: an endogenous regulator of apoptosis and growth suppression. , 1995, Immunology today.

[34]  G. Laurent,et al.  Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells , 1997, Oncogene.

[35]  P. Atadja,et al.  Increased activity of p53 in senescing fibroblasts. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Bielawska,et al.  Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. , 1993, The Journal of biological chemistry.

[37]  R. Testi,et al.  Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase , 1994, The Journal of experimental medicine.

[38]  E. White p53, guardian of Rb , 1994, Nature.

[39]  T. Shenk,et al.  Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Y. Hannun,et al.  Sphingolipid breakdown products: anti-proliferative and tumor-suppressor lipids. , 1993, Biochimica et biophysica acta.

[41]  Y. Hannun,et al.  Cytokine Response Modifier A (CrmA) Inhibits Ceramide Formation in Response to Tumor Necrosis Factor (TNF)-α: CrmA and Bcl-2 Target Distinct Components in the Apoptotic Pathway , 1997, The Journal of experimental medicine.

[42]  A. Bielawska,et al.  Role of Ceramide in Cellular Senescence (*) , 1995, The Journal of Biological Chemistry.

[43]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[44]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[45]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[46]  Y. Hannun,et al.  prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. , 1996, The Biochemical journal.

[47]  E. Alnemri,et al.  CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. , 1994, The Journal of biological chemistry.

[48]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[49]  K. Scotto,et al.  Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals , 1995, Cell.

[50]  T. Jacks,et al.  DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.

[51]  M. Kastan,et al.  Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Aebersold,et al.  Fas-induced apoptosis of T cells occurs independently of ceramide generation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  N. Davidson,et al.  Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. , 1993, Cancer research.

[54]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[55]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[56]  Y. Hannun Sphingolipid-Mediated Signal Transduction , 2013, Molecular Biology Intelligence Unit.

[57]  Y. Lazebnik,et al.  Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE , 1994, Nature.

[58]  W. R. Bishop,et al.  Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras- and sis-transformed normal rat kidney cells. , 1986, The Journal of biological chemistry.

[59]  Y. Hannun,et al.  Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. White,et al.  Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein , 1995, Molecular and cellular biology.

[61]  Muneesh Tewari,et al.  Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase , 1995, Cell.

[62]  A. Bielawska,et al.  Role for Ceramide in Cell Cycle Arrest (*) , 1995, The Journal of Biological Chemistry.

[63]  A. Levine,et al.  Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. , 1993, Oncogene.

[64]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[65]  A. Fornace,et al.  The p53-dependent gamma-ray response of GADD45. , 1994, Cancer research.

[66]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[67]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[68]  A. Haimovitz-Friedman,et al.  Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis , 1994, The Journal of experimental medicine.

[69]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[70]  S. Grant,et al.  Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. , 1994, The Journal of biological chemistry.

[71]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[72]  C. Borner,et al.  Bcl-2 interrupts the ceramide-mediated pathway of cell death. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Bielawska,et al.  Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Y. Hannun,et al.  Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. , 1991, The Journal of biological chemistry.

[75]  G. Demers,et al.  The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest , 1994, Journal of virology.

[76]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[77]  M. Kastan,et al.  DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. , 1994, Cold Spring Harbor symposia on quantitative biology.

[78]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.